ABSTRACT
The underrepresentation of different ancestry groups in large genomic datasets creates difficulties in interpreting the pathogenicity of monogenic variants. Genetic testing for individuals with non-European ancestry results in higher rates of uncertain variants and a greater risk of misclassification. We report a rare variant in the cardiac troponin T gene, TNNT2; NM_001001430.3: c.571-1G>A (rs483352835) identified via research-based whole exome sequencing in two unrelated probands of Oceanian ancestry with cardiac phenotypes.
The variant disrupts the canonical splice acceptor site, activating a cryptic acceptor and resulting in an in-frame deletion (p.Gln191del). The variant is rare in gnomAD v4.0.0 (13/780,762; 0.002%), with the highest frequency in South Asians (5/74,486; 0.007%) and has 16 ClinVar assertions (13 diagnostic clinical laboratories classify as variant of uncertain significance). There are at least 28 reported cases, many with Oceanian ancestry and diverse cardiac phenotypes. Indeed, among Oceanian-ancestry-matched datasets, the allele frequency ranges from 2.9-8.8% and is present in 2/4 (50%) Indigenous Australian alleles in Genome Asia 100K, with one participant being homozygous. With Oceanians deriving greater than 3% of their DNA from archaic genomes, we found c.571-1G>A in Vindija and Altai Neanderthal, but not the Altai Denisovan, suggesting an origin post Neanderthal divergence from modern humans 130-145 thousand years ago. Based on these data, we classify this variant as benign, and conclude it is not a monogenic cause of disease. Even with ongoing efforts to increase representation in genomics, we highlight the need for caution in assuming rarity of genetic variants in largely European datasets. Efforts to enhance diversity in genomic databases remain crucial.
Competing Interest Statement
JI receives research grant support from Bristol Myers Squibb unrelated to this work. CC is an employee of and has stock options in Genome Medical. VP receives research support from BioMarin Inc. and serves as consultant and/or scientific advisor for BioMarin, Inc. and Lexeo Therapeutics. JW has consulted for MyoKardia, Inc., Pfizer, Foresite Labs, and Health Lumen, and receives research support from Bristol Myers-Squibb. None of these activities are directly related to the work presented here. All other authors report no conflicts of interest.
Funding Statement
JI is the recipient of a National Heart Foundation of Australia Future Leader Fellowship (#106732). RDB is the recipient of a New South Wales Health Cardiovascular Disease Senior Scientist Grant. CS is the recipient of a National Health and Medical Research Council (NHMRC) Investigator Grant (#2016822) and a New South Wales Health Cardiovascular Disease Clinician Scientist Grant. This study uses data from the Pacific Islands Rheumatic Heart Disease Genetics Network. Funding was provided, in part, by a New South Wales (NSW) Health Cardiovascular Research Capacity Program early-mid career research grant, the British Heart Foundation (PG/14/26/30509; www.bhf.org.uk), the Medical Research Council UK (Fellowship G1100449; www.mrc.ac.uk), and the British Medical Association (Josephine Lansdell Grant; www.bma.org.uk). KM and JW are supported by the British Heart Foundation [FS/IPBSRF/22/27059, RE/18/4/34215] and the NIHR Imperial College Biomedical Research Centre (UK). JW is supported by the Sir Jules Thorn Charitable Trust [21JTA] and Medical Research Council (UK). The views expressed in this work are those of the authors and not necessarily those of the funders. For open access, the authors have applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval was obtained in accordance with policies applicable at Royal Prince Alfred Hospital Sydney Local Health District Human Research Ethics Committee (X15-0089 and X17-0350) for the original two patients, who provided written informed consent, and for collection of de-identified summary data from clinical laboratories and research centers used to inform variant prioritization and classification. Ethical approval for other summary case data including written informed consent from participants was granted by Melbourne Health Human Research Ethics Committee and New Zealand Ethics Committee. Ethical approval with a waiver of consent was granted by Stanford School of Medicine, USA; Pennsylvania University Medical Center, USA. All other data were in the public domain.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Additional data included and 2 additional authors.
